Accepted Manuscript published as JOE-19-0568.R1. Accepted for publication: 27-Feb-2020

UCN2: A new candidate influencing pancreatic β-cell adaptations to pregnancy

Sian.J.S.Simpson*, Lorna.I.F.Smith, Peter.M.Jones, James.E.Bowe

Department of Diabetes, School of Life Course Sciences, Faculty of Life Science and Medicine, King's College London, London, United Kingdom

Corresponding author:

Miss Sian.J.S.Simpson

Hodgkin Building

King's College London

Guy's Campus

London, SE1 1UL

sian.simpson@kcl.ac.uk

Short title

UCN2 and β-cell adaptations to pregnancy

Keywords

Insulin, islet, β-cell adaptation, pregnancy, corticotropin-releasing hormone, urocortin

Word count:

Abstract

The corticotropin releasing hormone (CRH) family of peptides, including urocortin (UCN) 1, 2 and 3, are established hypothalamic neuroendocrine peptides, regulating the physiological and behaviour responses to stress indirectly, via the hypothalamic-pituitary-adrenal (HPA) axis. More recently, these peptides have been implicated in diverse roles in peripheral organs through direct signalling, including in placental and pancreatic islet physiology. CRH has been shown to stimulate insulin release through activation of its cognate receptors, CRH receptor 1 (CRHR1) and 2. However, the physiological significance of this is unknown. We have previously reported that during mouse pregnancy, expression of CRH peptides increase in mouse placenta suggesting that these peptides may play a role in various biological functions associated with pregnancy, particularly the pancreatic islet adaptations that occur in the pregnant state to compensate for the physiological increase in maternal insulin resistance. In the current study, we show that mouse pregnancy is associated with increased circulating levels of UCN2 and that when we pharmacologically block endogenous CRHR signalling in pregnant mice, impairment of glucose tolerance is observed. This effect on glucose tolerance was comparable to that displayed with specific CRHR2 blockade and not with specific CRHR1 blockade. No effects on insulin sensitivity or the proliferative capacity of β-cells were detected. Thus, CRHR2 signalling appears to be involved in β-cell adaptive responses to pregnancy in the mouse, with endogenous placental UCN2 being the likely signal mediating this.

 Accepted Manuscript published as JOE-19-0568.R1. Accepted for publication: 27-Feb-2020

Introduction

The corticotropin releasing hormone (CRH) peptide family comprises CRH and the structurally related urocortin peptides (UCN1, UCN2 and UCN3). These neuroendocrine peptides are best known for their involvement in regulating the physiological and behavioural responses to stress, through the cognate G-protein coupled receptors (GPCRs), CRH receptor 1 (CRHR1) and CRH receptor 2 (CRHR2) (Bakshi et al., 2002; Chen et al., 1993; Lovenberg et al., 1995; Weninger et al., 1999), as part of the hypothalamic-pituitary-adrenal (HPA) axis. More recent evidence suggests additional, diverse, extra-hypothalamic roles for these peptides in peripheral organs (Chatoo et al., 2018; Chatzaki et al., 2019; Paschos et al., 2013). Thus, CRH expression has been reported in the adrenal gland and the gastrointestinal tract (Suda et al., 1984); UCN1 is expressed in heart, skin and adipose tissue (Kimura et al., 2002; Seres et al., 2004; Wierzbicka et al., 2017); and UCN2 and UCN3 have been detected in peripheral blood cells, skeletal muscle, pancreas and gestational tissues such as fetal membranes and placental villi (Petraglia et al., 2010). CRHR1 and CRHR2 are also expressed in a wide range of tissues, including cardiac myocytes, the adrenal gland, adipose tissue, skeletal muscle and skin (Hillhouse and Grammatopoulos, 2001), also suggesting physiological roles for the CRH peptide family unrelated to the HPA axis. However, under normal circumstances, levels of the peptides in the peripheral circulation are low (Ng et al., 2004; Sasaki et al., 1987), suggesting that the peptides may be produced locally to function as autocrine or paracrine agents in tissues where the respective receptors are also expressed (Li et al., 2013; van der Meulen et al., 2015; Zouboulis et al., 2002).

There is increasing evidence that the CRH peptide family may be involved in peripheral metabolic control via direct actions on insulin-secreting β-cells in pancreatic islets of

Langerhans (Li et al., 2007; Schmid et al., 2011). Both CRHR1 and CRHR2 are expressed in rodent (Kanno et al., 1999; Schmid et al., 2011) and human islets (Amisten et al., 2013), whilst *in vitro* administration of exogenous CRH stimulates insulin secretion from mouse and human islets as well as enhancing proliferation in neonatal rat β-cells (Huising et al., 2010). Similarly, β-cell derived UCN3 has been implicated in the local regulation of both insulin and glucagon release (Li et al., 2007). Despite the evidence demonstrating direct effects of exogenous CRH on islet function, the physiological relevance of this interaction is unclear, given the islets would not normally be exposed to significant levels of peptides of the CRH family. There is some evidence that placentally-derived CRH and urocortins are involved in various biological functions associated with pregnancy (Thomson, 2013; You et al., 2014). Thus, pregnancy represents one possible physiological state in which the effects of the CRH family on islet function may play a role.

During pregnancy, maternal insulin resistance increases and this is compensated for by increases in β-cell mass and enhanced insulin secretory responses to elevations in plasma glucose (Baeyens et al., 2016; Pasek and Gannon, 2013; Xue et al., 2010). We have recently reported an upregulation of CRH, UCN2 and UCN3 mRNA expression in mouse placenta on gestational day 12 (Drynda et al., 2018), which correlates to the initiation of β-cell adaptations in rodent pregnancy (Rieck and Kaestner, 2010). Similarly, in human pregnancy, levels of CRH in the peripheral circulation increase as gestation progresses (Campbell et al., 1987; Sasaki et al., 1987) and CRH immunoreactivity has been reported in human placenta (Grino et al., 1987), consistent with a placental source for the circulating CRH. In the current study, we have therefore investigated a potential role for the CRH peptide family in the regulation of glucose homeostasis during pregnancy.

 Accepted Manuscript published as JOE-19-0568.R1. Accepted for publication: 27-Feb-2020

Materials and methods

Animals

Female Institute of Cancer Research (ICR) mice (8-12 weeks of age, Envigo, Bicester, UK) were used for *in vivo* studies. This is a commonly used outbred mouse strain with very good reproductive and maternal characteristics. All animals were housed under controlled, pathogen free conditions (12-hour light/ dark cycle (0700 – 1900 hr lights on), temperature 22±2^{o}C) and provided with standard chow diet and water ad libitum. For timed pregnancy studies, female mice were mated with male ICR mice and the presence of vaginal plug assessed daily and denoted day 1 of pregnancy if present. Age-matched female mice were used for non-pregnant studies, with procedures carried out at the same time intervals as described for pregnancy studies. All procedures were conducted under approval by King's College London Animal Welfare and Ethical Review Board and were undertaken in accordance with United Kingdom Home Office Regulations.

Islet isolation and insulin secretion in vitro

For *in vitro* insulin secretion studies, pancreatic islets were isolated from female ICR mice via collagenase digestion of the exocrine pancreas, as described previously (Rackham et al., 2016). Isolated islets were subsequently maintained at 37^{o}C in RPMI (Sigma, UK) supplemented with 10% [vol./vol.] fetal bovine serum, 2 mmol/l glutamine and 100 U/ml penicillin/0.1 mg/ml streptomycin for 24 hours before use. Islets were loaded into a multi-channel, temperature controlled perifusion system, as described previously (Liu et al., 2013), and pre-perifused for 1 hour with physiological salt buffer (Bowe et al., 2019) containing 2 mmol/l glucose before being exposed to 20 mmol/l glucose in the presence or absence of the CRHR agonists, CRH (50 nmol/l, Sigma, UK), Stressin I (100 nmol/l, Tocris, UK) or UCN2

(100 nmol/l, Sigma, UK) at 37°C. Perifusate samples were collected every 2 minutes and insulin secretion was quantified using an in-house insulin radioimmunoassay (Jones et al., 1988).

In vivo osmotic minipump studies

Osmotic minipumps (ALZET®, Model 1002, Charles River, UK) were implanted subcutaneously into pregnant or non-pregnant mice to chronically administer test agents. Surgical implantation of osmotic minipumps was carried out on day 7 of pregnancy (or equivalent time interval for non-pregnant mice) under isoflurane anaesthesia (Isothesia®, Henry Schein®). Minipumps were loaded with physiological saline, non-specific CRHR antagonist (α-helical CRF_{9-41}, 1 mg/ml, Tocris, UK) or receptor specific CRHR antagonists, Antalarmin hydrochloride (1 mg/ml, Tocris, UK) or Antisauvagine-30 (3 mg/ml, Tocris, UK) for CRHR1 and R2, respectively. Test agents were delivered at a rate of 0.25 µl /hour for a total period of 11 days. Assessment of glucose tolerance and insulin tolerance were conducted on gestational days 16 and 18, respectively.

Assessment of glucose homeostasis

Intraperitoneal glucose tolerance tests (IPGTT) were conducted on day 16 of gestation. Mice were fasted from 0900 for 6 hours and then administered with glucose (2 g/kg, Sigma, UK). Blood sampling was performed by small tail prick at time points 0, 15, 30, 60, 90 and 120 min following glucose administration to determine blood glucose levels using an Accu-Chek glucose meter (Roche Diagnostics, UK). Intraperitoneal insulin tolerance tests (IPITT) were conducted on day 18 of gestation. Mice were again fasted from 0900 for 6 hours prior to metabolic testing and were subsequently administered with insulin (0.75 IU/kg, Sigma, UK).

 Accepted Manuscript published as JOE-19-0568.R1. Accepted for publication: 27-Feb-2020

Blood sampling was performed by small tail prick at time points 0, 15, 30, 45 and 60 min following insulin injection to determine blood glucose levels.

Measurements of circulating CRH-related peptides

On day 18, animals were euthanised by intraperitoneal injection of terminal anaesthesia (Euthatal®, Merial Animal Health Ltd, UK) and terminal blood samples were collected via cardiac puncture into sterile heparin-coated tubes. Samples were also collected from control pregnant mice on day 16. Samples were centrifuged (1,800 rcf, 20 minutes, 4°C) and the subsequent plasma stored at -20°C for later assay of circulating peptide levels using commercially available ELISA kits (CRH: CEA835Mu, Cloud-Clone Corp, USA; UCN1: CEA231Mu, Cloud-Clone Corp, USA; UCN2: MOFI00425, ELISAGenie, UK; UCN3: CED140Mu, Cloud-Clone Corp, USA) following the manufacturers' instructions.

Quantification of mRNA expression

Isolated female islets from non-pregnant and pregnant (day 16) mice were immediately snap frozen in liquid nitrogen following purification from the exocrine pancreas for subsequent RNA extraction using RNeasy Mini Kit (Qiagen, UK) and High Capacity cDNA Reverse Transcription Kit (Applied Biosystems™, UK) for cDNA synthesis, as described previously (Drynda et al., 2018). Placenta samples were also collected after termination at day 18 of pregnancy and snap frozen. RNA extraction and cDNA conversion were conducted as described above. Islet CRH receptor and placental CRH ligand mRNA expression was subsequently quantified by quantitative reverse transcription polymerase chain reaction (qRT-PCR) using SYBR Green PCR Kit (QuantiTect, Qiagen, UK) and a LC96 Light Cycler (Roche Diagnostics, UK). QuantiTect primer assays were used for expression analysis of genes of interest using Glyceraldehyde 3-phosphate dehydrogenase (*Gapdh*) as the housekeeping gene (Mouse *Crh*- QT01055789, *Ucn1*- QT00326879, *Ucn2*-QT01556534,

Ucn3-QT00302267, *Crhr1*-QT00106232, *Crhr2*-QT00151543, *Gapdh*-QT01658692, Qiagen, UK).

Assessment of β-cell mass

For osmotic minipump studies, bromo-deoxy-uridine (BrdU, 1 mg/ml, Sigma, UK) was administered in the drinking water from day 14 to day 18 of pregnancy with fresh BrdU drinking water being replaced every two days. After termination at day 18, pancreata were dissected, fixed in 4% paraformaldehyde (Sigma, UK) and embedded in paraffin wax before being cut into 5µm thick sections using Leica microtome (RM2255). Representative sections (3-4 sections per animal), approximately 150 µm apart, were co-stained with guinea pig anti-insulin antibody (1:200, Dako, UK) to visualise islet β-cells and monoclonal mouse anti-BrdU antibody (1:100, Sigma, UK) to identify proliferating cells as previously described (Bowe et al., 2019). Images were taken on Nikon Eclipse TE2000-U fluorescent microscope and quantification of BrdU positive β-cells and β-cell area was performed using ImageJ 1.49c software.

Statistical analysis

Statistical analysis was performed using GraphPad Prism 8.0 software. For comparison between two groups, unpaired, two-tailed students t-test was used. For *in vivo* glucose and insulin tolerance tests, two-way repeated measures ANOVA was used, followed by Tukey's multiple comparison test to identify significance between multiple groups.

Results

CRH receptor gene expression profile in pregnancy

 Accepted Manuscript published as JOE-19-0568.R1. Accepted for publication: 27-Feb-2020

Islets isolated from non-pregnant and pregnant (d.16) female mice expressed both *Crhr1* and *Crhr2* mRNAs, as shown in Figure 1. As expected, *Crhr1* expression in islets was higher than *Crhr2* expression, displaying an analogous expression pattern for the receptors to that in the pituitary, a classical target for CRH. Islet *Crhr1* mRNA expression was significantly reduced during pregnancy compared to non-pregnant levels (Fig. 1A), whereas islet *Crhr2* mRNA levels were unchanged between non-pregnant and pregnant animals (Fig. 2B). Thus, islets express receptors for the entire CRH family of peptides.

Effects of CRH receptor stimulation on insulin secretion

Activating either CRHR1 or CRHR2 enhanced glucose-induced insulin secretion from isolated mouse islets in a dynamic perifusion system, as shown in Figure 2. Exposure to 20 mmol/l glucose initiated a rapid increase in insulin secretion, which was further potentiated by the addition of CRH (acting as a non-specific CRHR1 and CRHR2 agonist, Fig. 2A); Stressin I (a CRHR1 specific agonist, Fig. 2C); or of UCN2 (a CRHR2 specific agonist, Fig. 2E). Area under the curve quantification of glucose stimulated insulin secretion (30-50 min) confirms the significant potentiation of insulin secretion in the presence of stimulatory concentrations of glucose, induced by all CRH receptor agonists tested (Fig. 2B, D, F). CRHR agonists had no significant effect on insulin secretion at a sub-stimulatory concentration of glucose (Data not shown, 2 mmol/l glucose: Control: 0.056 ± 0.010 ng/islet/hr vs + 50 nmol/l CRH: 0.045 ± 0.009 vs + 100 nmol/l Stressin I: 0.034 ± 0.007 vs + 100 nmol/l Ucn2: 0.053 ± 0.008, mean ± SEM, n=9 observations $p>0.999$). Thus, activation of CRHR1 or CRHR2 potentiates glucose-stimulated insulin secretion from islet β-cells.

Circulating CRH and urocortin profile during pregnancy

qRT-PCR measurements demonstrated that mRNAs for *Crh*, *Ucn1*, *Ucn2* and *Ucn3* were all expressed by mouse placenta at day 18 at similar levels (Fig. 3A), confirming our previous observations (Drynda et al., 2018). Furthermore, all four peptides were detected in the peripheral circulation, with UCN2 being the most abundant circulating CRHR agonist (Fig. 3B). The circulating levels of CRH, UCN1 and UCN3 were unchanged between non-pregnant and pregnant female mice. However, circulating levels of UCN2 were elevated almost 2-fold by day 16 of pregnancy when compared to age-matched virgin female controls (Fig. 3B). Thus, the pancreatic islets are likely to be exposed to elevated levels of UCN2 during pregnancy, with the placenta being the most likely source for the increased levels. Therefore, the candidate ligand of the CRH family to play a physiological role in the islet adaptation to pregnancy appears to be UCN2.

Effect of pharmacologically blocking endogenous CRH receptor signalling during pregnancy

The consequences of pharmacological blockade of CRH receptor signalling *in vivo* was assessed in both non-pregnant and pregnant mice, revealing a pregnancy- and receptor-specific phenotype, as shown in Figure 4. As expected, intraperitoneal administration of glucose, elevated blood glucose levels within 15 minutes in both pregnant and non-pregnant mice (Fig. 4A, E). Chronic pharmacological blockade of total CRHR signalling during pregnancy with a non-selective antagonist, α-helical CRF_{9-41}, resulted in a mild impairment to glucose tolerance, with significantly higher blood glucose concentrations at 15 minutes after glucose administration, compared to saline controls (Fig. 4A). Chronic administration of the CRHR2 antagonist, Antisauvagine-30, resulted in a similar impairment to glucose tolerance in pregnant mice, but not in animals treated with the specific CRHR1 antagonist, Antalarmin hydrochloride (Fig. 4A, B). These data are consistent with an endogenous ligand, acting via

 Accepted Manuscript published as JOE-19-0568.R1. Accepted for publication: 27-Feb-2020

CRHR2, playing a physiological role in maintaining normal glucose tolerance during pregnancy. All pregnant mice were insulin resistant by day 18 of pregnancy as indicated by the failure to respond to exogenous insulin administration and lowering of blood glucose, however, none of the CRHR antagonists had any detectable effects on insulin sensitivity (Fig. 4C, D). Chronic treatment of non-pregnant female mice with α-helical CRF_{9-41} to block total CRHR signalling had no significant effect on glucose tolerance or insulin sensitivity (Fig. 4E-H). Given the lack of effect of α-helical CRF_{9-41}, receptor specific antagonists were not tested outside of pregnancy. Thus, CRHR2 activation by an endogenous ligand is involved in maintaining glucose homeostasis specifically during pregnancy.

In addition to effects on whole body glucose homeostasis, pregnancy in mice is also associated with an increased rate of β-cell proliferation to increase the functional β-cell mass (Rieck and Kaestner, 2010). This was evaluated by $BrdU^+$ β-cell staining (Fig. 5A, B). Chronic blockade of total CRHR signalling during pregnancy using α-helical CRH_{9-41}, had no significant effects on β-cell proliferation, β-cell size or the average $insulin^+$ β-cell area, as shown in Figure 5C-E. The effects of CRHR activation on glucose homeostasis during pregnancy are therefore most likely direct effects on the β-cell to enhance insulin secretion rather than to increase the β-cell mass.

Discussion

During pregnancy, the metabolic profile of the mother adapts to ensure a sufficient supply of energy for the developing fetus. A progressive increase in maternal insulin resistance across pregnancy represents a key mechanism for increasing fuel availability to the fetus (Freemark, 2006; Newbern and Freemark, 2011). This insulin resistance is compensated for by an

increase in the maternal functional β-cell mass and enhanced insulin secretory responses (Baeyens et al., 2016). Failure of the β-cell to adapt to the maternal metabolic load can lead to maternal glucose intolerance and, eventually, to overt gestational diabetes (Plows et al., 2018; Zhang et al., 2010). In rodent models, the early β-cell adaptations to pregnancy involve non-placental signals (Drynda et al., 2015), but as placentation is established and pregnancy progresses, the placenta becomes an important endocrine organ, secreting numerous hormonal signals, which influence maternal and fetal physiology (Jansson, 2016). The lactogenic hormones, prolactin and placental lactogen, are important pregnancy associated signals, well-established to act via β-cell prolactin receptors to induce β-cell mass expansion and enhance insulin secretion (Brelje et al., 1993; Huang et al., 2009; Sorenson et al., 1993; Vasavada et al., 2000). These effects may be mediated, at least in part, by an upregulation of intra-islet serotonin (Kim et al., 2010; Ohara-Imaizumi et al., 2013). However, the mouse placenta expresses approximately 80 different ligands for which β-cells express the cognate GPCRs (Drynda et al., 2018) and it is unlikely that the lactogenic hormones are the only signals involved in regulating islet adaptations. These placental ligands include a number of peptides more usually associated with hypothalamic neuroendocrine functions. We have recently identified kisspeptin as an important placental signal regulating β-cell function during pregnancy (Bowe et al., 2019). The current study extends these observations to implicate another classical hypothalamic neuroendocrine system, the CRH peptide family, in placental control of β-cell function.

The expression profile of CRH receptors in mouse islets is consistent with previous reports confirming the expression of both *Crhr1* and *Crhr2* using mouse (Huising et al., 2011) or human (Amisten et al., 2013) islets. These observations suggest that islet cells have an innate capacity to recognise and respond to circulating CRH and the urocortin peptides. The

 Accepted Manuscript published as JOE-19-0568.R1. Accepted for publication: 27-Feb-2020

299 decreased expression levels of *Crhr1* during pregnancy is also suggestive of a shift in the
300 receptor ratio to potentially direct *Crhr2* signalling under the influence of placental signals.
301 Accordingly, our *in vitro* measurements of insulin secretion from isolated islets,
302 demonstrated that activation of either CRHR1 or CRHR2 significantly potentiates glucose-
303 stimulated insulin secretion (GSIS). Similar to other β-cell GPCRs, activation of CRHR1 and
304 CRHR2 only enhanced insulin secretion in the presence of a stimulatory concentration of
305 glucose, suggesting that the physiological function of receptor activation is to module the
306 extent of the insulin secretory response to elevated glucose concentrations, rather than to
307 initiate secretion. Our dynamic measurements of insulin secretion from isolated islets
308 correspond with studies using mouse or human islets in static incubations (Huising et al.,
309 2010; O'Carroll et al., 2008) and imply that increased levels of CRHR agonists will result in
310 an enhanced glucose-induced insulin secretory response. However, whilst previous studies
311 have suggested a role for the CRH family in regulating islet function, the physiological
312 purpose of this effect was unclear.
313
314 Placental expression and secretion of CRHR agonists is contentious. Earlier studies detected
315 CRH mRNA and immunoreactivity in placentae from humans and non-human primates (Frim
316 et al., 1988; Robinson et al., 1989; Sasaki et al., 1987), but failed to detect it in non-primate
317 species including lemur, guinea pig and rat (Robinson et al., 1989). In human pregnancy,
318 levels of CRH in the peripheral circulation increase as gestation progresses (Campbell et al.,
319 1987; Sasaki et al., 1987). It has thus been suggested that the physiological purpose of this
320 increase is in regulating parturition through modulation of signals controlling myometrium
321 contractility and inflammation (McLean et al., 1995; Thomson, 2013; You et al., 2014).
322 Contrary to human pregnancy, placental CRH in rodents is not thought to have a significant
323 role in initiating parturition, with evidence of a more influential role in facilitating

implantation particularly during murine pregnancy (Athanassakis et al., 1999). Increased expression of UCN2 mRNA and protein has been reported in both human and mouse gestational tissues (including fetal membranes, myometrium and placenta) (Voltolini et al., 2015), although conflicting reports suggest no significant change in circulating levels of UCN1, UCN2 or UCN3 during human pregnancy (Pepels et al., 2010). In the current study we detected the expression of mRNAs for all members of the CRH family in mouse placenta. Circulating levels of CRH, UCN1 and UCN3 were unchanged in pregnant and non-pregnant mice, suggesting that these ligands are not released by the mouse placenta at significant levels, however circulating levels of UCN2 were significantly increased during gestation. The circulating concentrations of UCN2 which we detected during pregnancy are close to the reported EC50 values for CRHR2 (Dautzenberg et al., 2004; Hauger et al., 2003; Patel et al., 2012) and are consistent with β-cell CRHR2 activation in response to pregnancy signals. These observations are also consistent with the placenta being the source of the increased circulating UCN2 during mouse pregnancy, analogous to the increases in placentally derived kisspeptin in the circulation during mouse and human pregnancy (Bowe et al., 2019; Dhillo et al., 2006; Mark et al., 2013), and suggest that it may potentially play a physiological role during pregnancy. However, it cannot be ruled out that the pregnancy-associated UCN2 derives from an alternative peripheral source, such as skin or skeletal muscle where it is also highly expressed (Chen et al., 2004).

Irrespective of its source, our *in vivo* studies suggest a role for circulating UCN2 in the regulation of β-cell insulin secretory responses during mouse pregnancy. Thus, pharmacological blockade of CRHR2 impaired glucose tolerance in pregnant mice, but a similar impairment was not observed with CRHR1 blockade, nor in non-pregnant females. The lack of effect of *in vivo* CRHR blockade on insulin resistance during pregnancy suggests

 Accepted Manuscript published as JOE-19-0568.R1. Accepted for publication: 27-Feb-2020

that the impaired glucose tolerance reflects a β-cell targeted effect, consistent with our *in vitro* observations of enhanced insulin secretion in response to CRHR2 activation. Most placental hormones involved in β-cell adaptations to pregnancy exert dual effects to acutely increase the rate of insulin secretion from individual β-cells, and chronically to induce expansion of the functional β-cell pool. These compensatory mechanisms ensure that the mother can sustain a robust insulin secretory response to elevated plasma glucose, especially in the prevailing insulin resistant environment. Under normal circumstances the rate of β-cell proliferation is very low, but chronic exposure to lactogenic hormones (Baeyens et al., 2016; Brelje et al., 1993; Huang et al., 2009) or to kisspeptin (Bowe et al., 2019) during gestation increases the rate of β-cell proliferation, and so increases the functional β-cell mass both *in vitro* and *in vivo*. In the current study, chronic blockade of total CRH receptors during pregnancy had no significant effects on β-cell size or proliferation, nor on the overall β-cell mass. This provides further evidence that the impairment to glucose tolerance *in vivo* during pregnancy, is due to an endogenous ligand, specifically targeting CRHR2, enhancing β-cell insulin secretion. The physiological significance of these differences in modes of action of placental factors is uncertain, but there may be therapeutic advantages in the ability of UCN2 to enhance glucose-induced insulin secretion without targeting the clinical challenges of manipulating β-cell proliferation.

The variability of maternal glycaemia throughout pregnancy can range from normal/mild glucose intolerance, to severe in the case of gestational diabetes. The pharmacological blockade of CRHR2 signalling during pregnancy appears to reveal a transient and mild glucose intolerance in comparison to the more profound defect in glucose tolerance displayed by mutant PRLR mice (Huang et al., 2009). Given the importance of maintaining appropriate maternal glycaemic control during pregnancy, it is perhaps not surprising that there are

multiple control mechanisms that ensure an integrated β-cell insulin secretory response. Therefore, the mild phenotype displayed may have been compensated by complementary signals to prevent major disruptions to glucose homeostasis.

In summary, we have demonstrated that CRHR2 signalling is involved in β-cell adaptive responses to pregnancy in the mouse, with endogenous placental UCN2 being the likely signal mediating this adaptation. Unlike other identified placental signals, the effects of UCN2 appear to be confined to amplifying glucose-induced insulin secretion without concomitant alterations in the β-cell mass. Blocking the endogenous CRHR2 agonist during gestation induces a mild glucose intolerance rather than overt gestational diabetes suggesting that UCN2 may act in concert with other placental signals to fine-tune the compensatory β-cell adaptations to maternal insulin resistance during pregnancy. Deciphering the interplay between these different signals will lead to a more comprehensive understanding of the pathophysiology of gestational diabetes and may offer novel diagnostic or therapeutic strategies.

Declaration of interest, Funding and Acknowledgements

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. This work was supported by grant funding from both the Diabetes Research and Wellness Foundation (DRWF) (SCA/OF/12/18) and the Medical Research Council (MRC) Doctoral Training Program studentship (Sian JS Simpson).

 Accepted Manuscript published as JOE-19-0568.R1. Accepted for publication: 27-Feb-2020

Bibliography

Amisten, S., Salehi, A., Rorsman, P., Jones, P.M., Persaud, S.J., 2013. An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans. Pharmacol. Ther. 139, 359–391. https://doi.org/10.1016/j.pharmthera.2013.05.004

Athanassakis, I., Farmakiotis, V., Aifantis, I., Gravanis, A., Vassiliadis, S., 1999. Expression of corticotrophin-releasing hormone in the mouse uterus: participation in embryo implantation. J. Endocrinol. 163, 221–227. https://doi.org/10.1677/joe.0.1630221

Baeyens, L., Hindi, S., Sorenson, R.L., German, M.S., 2016. β-Cell Adaptation in Pregnancy. Diabetes Obes Metab 18, 63–70. https://doi.org/10.1111/dom.12716

Bakshi, V.P., Smith-Roe, S., Newman, S.M., Grigoriadis, D.E., Kalin, N.H., 2002. Reduction of Stress-Induced Behavior by Antagonism of Corticotropin-Releasing Hormone 2 (CRH2) Receptors in Lateral Septum or CRH1 Receptors in Amygdala. J. Neurosci. 22, 2926–2935. https://doi.org/10.1523/JNEUROSCI.22-07-02926.2002

Bowe, J.E., Hill, T.G., Hunt, K.F., Smith, L.I.F., Simpson, S.J.S., Amiel, S.A., Jones, P.M., 2019. A role for placental kisspeptin in **β** cell adaptation to pregnancy. JCI Insight 4. https://doi.org/10.1172/jci.insight.124540

424 Brelje, T.C., Scharp, D.W., Lacy, P.E., Ogren, L., Talamantes, F., Robertson, M., Friesen,
425 H.G., Sorenson, R.L., 1993. Effect of homologous placental lactogens, prolactins, and growth
426 hormones on islet B-cell division and insulin secretion in rat, mouse, and human islets:
427 implication for placental lactogen regulation of islet function during pregnancy.
428 Endocrinology 132, 879–887. https://doi.org/10.1210/endo.132.2.8425500
429 Campbell, E.A., Linton, E.A., Wolfe, C.D.A., Scraggs, P.R., Jones, M.T., Lowry, P.J., 1987.
430 Plasma Corticotropin-Releasing Hormone Concentrations During Pregnancy and Parturition.
431 None 64, 1054–1059. https://doi.org/10.1210/jcem-64-5-1054
432 Chatoo, M., Li, Y., Ma, Z., Coote, J., Du, J., Chen, X., 2018. Involvement of Corticotropin-
433 Releasing Factor and Receptors in Immune Cells in Irritable Bowel Syndrome. Front.
434 Endocrinol. 9. https://doi.org/10.3389/fendo.2018.00021
435 Chatzaki, E., Kefala, N., Drosos, I., Lalidou, F., Baritaki, S., 2019. Do urocortins have a role
436 in treating cardiovascular disease? Drug Discovery Today 24, 279–284.
437 https://doi.org/10.1016/j.drudis.2018.09.004
438 Chen, A., Blount, A., Vaughan, J., Brar, B., Vale, W., 2004. Urocortin II Gene Is Highly
439 Expressed in Mouse Skin and Skeletal Muscle Tissues: Localization, Basal Expression in
440 Corticotropin-Releasing Factor Receptor (CRFR) 1- and CRFR2-Null Mice, and Regulation
441 by Glucocorticoids. Endocrinology 145, 2445–2457. https://doi.org/10.1210/en.2003-1570
442 Chen, R., Lewis, K.A., Perrin, M.H., Vale, W.W., 1993. Expression cloning of a human
443 corticotropin-releasing-factor receptor. Proc. Natl. Acad. Sci. U.S.A. 90, 8967–8971.
444 Dautzenberg, F.M., Gutknecht, E., Linden, I.V. der, Olivares-Reyes, J.A., Dürrenberger, F.,
445 Hauger, R.L., 2004. Cell-type specific calcium signaling by corticotropin-releasing factor
446 type 1 (CRF1) and 2a (CRF2(a)) receptors: phospholipase C-mediated responses in human
447 embryonic kidney 293 but not SK-N-MC neuroblastoma cells. Biochemical Pharmacology
448 68, 1833–1844. https://doi.org/10.1016/j.bcp.2004.07.013

 Accepted Manuscript published as JOE-19-0568.R1. Accepted for publication: 27-Feb-2020

449 Dhillo, W.S., et al.., 2006. Plasma kisspeptin is raised in patients with gestational
450 trophoblastic neoplasia and falls during treatment. Am. J. Physiol. Endocrinol. Metab. 291,
451 E878-884. https://doi.org/10.1152/ajpendo.00555.2005
452 Drynda, R., Persaud, S.J., Bowe, J.E., Jones, P.M., 2018. The Placental Secretome:
453 Identifying Potential Cross-Talk Between Placenta and Islet β-Cells. Cell. Physiol. Biochem.
454 45, 1165–1171. https://doi.org/10.1159/000487357
455 Drynda, R., Peters, C.J., Jones, P.M., Bowe, J.E., 2015. The role of non-placental signals in
456 the adaptation of islets to pregnancy. Horm. Metab. Res. 47, 64–71. https://doi.org/10.1055/s-
457 0034-1395691
458 Freemark, M., 2006. Regulation of Maternal Metabolism by Pituitary and Placental
459 Hormones: Roles in Fetal Development and Metabolic Programming. HRP 65, 41–49.
460 https://doi.org/10.1159/000091505
461 Frim, D.M., Emanuel, R.L., Robinson, B.G., Smas, C.M., Adler, G.K., Majzoub, J.A., 1988.
462 Characterization and gestational regulation of corticotropin-releasing hormone messenger
463 RNA in human placenta. J Clin Invest 82, 287–292.
464 Grino, M., Chrousos, G.P., Margioris, A.N., 1987. The corticotropin releasing hormone gene
465 is expressed in human placenta. Biochem. Biophys. Res. Commun. 148, 1208–1214.
466 https://doi.org/10.1016/s0006-291x(87)80261-9
467 Hauger, R.L., Grigoriadis, D.E., Dallman, M.F., Plotsky, P.M., Vale, W.W., Dautzenberg,
468 F.M., 2003. International Union of Pharmacology. XXXVI. Current Status of the
469 Nomenclature for Receptors for Corticotropin-Releasing Factor and Their Ligands.
470 Pharmacol Rev 55, 21–26. https://doi.org/10.1124/pr.55.1.3
471 Hillhouse, E.W., Grammatopoulos, D.K., 2001. Characterising the Corticotropin-releasing
472 Hormone (CRH) Receptors Mediating CRH and Urocortin Actions During Human
473 Pregnancy and Labour. Stress 4, 235–246. https://doi.org/10.3109/10253890109014748

474 Huang, C., Snider, F., Cross, J.C., 2009. Prolactin receptor is required for normal glucose
475 homeostasis and modulation of beta-cell mass during pregnancy. Endocrinology 150, 1618–
476 1626. https://doi.org/10.1210/en.2008-1003
477 Huising, M.O., Pilbrow, A.P., Matsumoto, M., van der Meulen, T., Park, H., Vaughan, J.M.,
478 Lee, S., Vale, W.W., 2011. Glucocorticoids Differentially Regulate the Expression of CRFR1
479 and CRFR2α in MIN6 Insulinoma Cells and Rodent Islets. Endocrinology 152, 138–150.
480 https://doi.org/10.1210/en.2010-0791
481 Huising, M.O., van der Meulen, T., Vaughan, J.M., Matsumoto, M., Donaldson, C.J., Park,
482 H., Billestrup, N., Vale, W.W., 2010. CRFR1 is expressed on pancreatic beta cells, promotes
483 beta cell proliferation, and potentiates insulin secretion in a glucose-dependent manner. Proc.
484 Natl. Acad. Sci. U.S.A. 107, 912–917. https://doi.org/10.1073/pnas.0913610107
485 Jansson, T., 2016. Placenta plays a critical role in maternal–fetal resource allocation.
486 Proceedings of the National Academy of Sciences 113, 11066–11068.
487 https://doi.org/10.1073/pnas.1613437113
488 Jones, P.M., SALMONt, D.M.W., Howell, S.L., 1988. Protein phosphorylation in electrically
489 permeabilized islets of Langerhans 254, 7.
490 Kanno, T., Suga, S., Nakano, K., Kamimura, N., Wakui, M., 1999. Corticotropin-releasing
491 factor modulation of Ca2+ influx in rat pancreatic beta-cells. Diabetes 48, 1741–1746.
492 Kim, H., et al., 2010. Serotonin regulates pancreatic beta cell mass during pregnancy. Nat.
493 Med. 16, 804–808. https://doi.org/10.1038/nm.2173
494 Kimura, Y., Takahashi, K., Totsune, K., Muramatsu, Y., Kaneko, C., Darnel, A.D., Suzuki,
495 T., Ebina, M., Nukiwa, T., Sasano, H., 2002. Expression of urocortin and corticotropin-
496 releasing factor receptor subtypes in the human heart. J. Clin. Endocrinol. Metab. 87, 340–
497 346. https://doi.org/10.1210/jcem.87.1.8160

 Accepted Manuscript published as JOE-19-0568.R1. Accepted for publication: 27-Feb-2020

498 Li, C., Chen, P., Vaughan, J., Lee, K.-F., Vale, W., 2007. Urocortin 3 regulates glucose-
499 stimulated insulin secretion and energy homeostasis. Proc. Natl. Acad. Sci. U.S.A. 104,
500 4206–4211. https://doi.org/10.1073/pnas.0611641104
501 Li, J., et al., 2013. Urocortin 2 autocrine/paracrine and pharmacologic effects to activate
502 AMP-activated protein kinase in the heart. PNAS 110, 16133–16138.
503 https://doi.org/10.1073/pnas.1312775110
504 Liu, B., Hassan, Z., Amisten, S., King, A.J., Bowe, J.E., Huang, G.C., Jones, P.M., Persaud,
505 S.J., 2013. The novel chemokine receptor, G-protein-coupled receptor 75, is expressed by
506 islets and is coupled to stimulation of insulin secretion and improved glucose homeostasis.
507 Diabetologia 56, 2467–2476. https://doi.org/10.1007/s00125-013-3022-x
508 Lovenberg, T.W., Liaw, C.W., Grigoriadis, D.E., Clevenger, W., Chalmers, D.T., De Souza,
509 E.B., Oltersdorf, T., 1995. Cloning and characterization of a functionally distinct
510 corticotropin-releasing factor receptor subtype from rat brain. Proc. Natl. Acad. Sci. U.S.A.
511 92, 836–840.
512 Mark, P.J., Jones, M.L., Lewis, J.L., Waddell, B.J., Smith, J.T., 2013. Kiss1 and Kiss1r
513 mRNA expression in the rat placenta: changes with gestational age and regulation by
514 glucocorticoids. Placenta 34, 657–662. https://doi.org/10.1016/j.placenta.2013.04.012
515 McLean, M., Bisits, A., Davies, J., Woods, R., Lowry, P., Smith, R., 1995. A placental clock
516 controlling the length of human pregnancy. Nature Medicine 1, 460–463.
517 https://doi.org/10.1038/nm0595-460
518 Newbern, D., Freemark, M., 2011. Placental hormones and the control of maternal
519 metabolism and fetal growth. Curr Opin Endocrinol Diabetes Obes 18, 409–416.
520 https://doi.org/10.1097/MED.0b013e32834c800d

521 O'Carroll, A.-M., Howell, G.M., Roberts, E.M., Lolait, S.J., 2008. Vasopressin potentiates
522 corticotropin-releasing hormone-induced insulin release from mouse pancreatic β-cells. J
523 Endocrinol 197, 231–239. https://doi.org/10.1677/JOE-07-0645
524 Ohara-Imaizumi, M., et al., 2013. Serotonin regulates glucose-stimulated insulin secretion
525 from pancreatic β cells during pregnancy. Proc. Natl. Acad. Sci. U.S.A. 110, 19420–19425.
526 https://doi.org/10.1073/pnas.1310953110
527 Paschos, K., Chouridou, E., Koureta, M., Lambropoulou, M., Kolios, G., Chatzaki, E., 2013.
528 The corticotropin releasing factor system in the liver: expression, actions and possible
529 implications in hepatic physiology and pathology. HORMONES 12, 236–245.
530 https://doi.org/10.14310/horm.2002.1407
531 Pasek, R.C., Gannon, M., 2013. Advancements and challenges in generating accurate animal
532 models of gestational diabetes mellitus. Am. J. Physiol. Endocrinol. Metab. 305, E1327-
533 1338. https://doi.org/10.1152/ajpendo.00425.2013
534 Patel, K., Rademaker, M., Kirkpatrick, C., Charles, C., Fisher, S., Yandle, T., Richards, A.,
535 2012. Comparative pharmacokinetics and pharmacodynamics of urocortins 1, 2 and 3 in
536 healthy sheep. British Journal of Pharmacology 166, 1916–1925.
537 https://doi.org/10.1111/j.1476-5381.2012.01904.x
538 Pepels, P.P.L.M., Spaanderman, M.E.A., Hermus, A.R.M.M., Lotgering, F.K., Sweep,
539 C.G.J., 2010. Placental urocortin-2 and -3: endocrine or paracrine functioning during healthy
540 pregnancy? Placenta 31, 475–481. https://doi.org/10.1016/j.placenta.2010.03.012
541 Petraglia, F., Imperatore, A., Challis, J.R.G., 2010. Neuroendocrine Mechanisms in
542 Pregnancy and Parturition. Endocrine Reviews 31, 783–816. https://doi.org/10.1210/er.2009-
543 0019

 Accepted Manuscript published as JOE-19-0568.R1. Accepted for publication: 27-Feb-2020

544 Plows, J.F., Stanley, J.L., Baker, P.N., Reynolds, C.M., Vickers, M.H., 2018. The
545 Pathophysiology of Gestational Diabetes Mellitus. Int J Mol Sci 19.
546 https://doi.org/10.3390/ijms19113342
547 Rackham, C.L., Vargas, A.E., Hawkes, R.G., Amisten, S., Persaud, S.J., Austin, A.L.F.,
548 King, A.J.F., Jones, P.M., 2016. Annexin A1 Is a Key Modulator of Mesenchymal Stromal
549 Cell–Mediated Improvements in Islet Function. Diabetes 65, 129–139.
550 https://doi.org/10.2337/db15-0990
551 Rieck, S., Kaestner, K.H., 2010. Expansion of beta-cell mass in response to pregnancy.
552 Trends Endocrinol. Metab. 21, 151–158. https://doi.org/10.1016/j.tem.2009.11.001
553 Robinson, B.G., Arbiser, J.L., Emanuel, R.L., Majzoub, J.A., 1989. Species-specific placental
554 corticotropin releasing hormone messenger RNA and peptide expression. Molecular and
555 Cellular Endocrinology 62, 337–341. https://doi.org/10.1016/0303-7207(89)90022-1
556 Sasaki, A., Shinkawa, O., Margioris, A.N., Liotta, A.S., Sato, S., Murakami, O., Go, M.,
557 Shimizu, Y., Hanew, K., Yoshinaga, K., 1987. Immunoreactive corticotropin-releasing
558 hormone in human plasma during pregnancy, labor, and delivery. J. Clin. Endocrinol. Metab.
559 64, 224–229. https://doi.org/10.1210/jcem-64-2-224
560 Schmid, J., et al., 2011. Modulation of pancreatic islets-stress axis by hypothalamic releasing
561 hormones and 11β-hydroxysteroid dehydrogenase. PNAS 108, 13722–13727.
562 https://doi.org/10.1073/pnas.1110965108
563 Seres, J., Bornstein, S.R., Seres, P., Willenberg, H.S., Schulte, K.M., Scherbaum, W.A.,
564 Ehrhart-Bornstein, M., 2004. Corticotropin-Releasing Hormone System in Human Adipose
565 Tissue. None 89, 965–970. https://doi.org/10.1210/jc.2003-031299
566 Sorenson, R.L., Brelje, T.C., Roth, C., 1993. Effects of steroid and lactogenic hormones on
567 islets of Langerhans: a new hypothesis for the role of pregnancy steroids in the adaptation of

568 islets to pregnancy. Endocrinology 133, 2227–2234.
569 https://doi.org/10.1210/endo.133.5.8404674
570 Suda, T., Tomori, N., Tozawa, F., Mouri, T., Demura, H., Shizume, K., 1984. Distribution
571 and Characterization of Immunoreactive Corticotropin-Releasing Factor in Human Tissues.
572 None 59, 861–866. https://doi.org/10.1210/jcem-59-5-861
573 Thomson, M., 2013. The physiological roles of placental corticotropin releasing hormone in
574 pregnancy and childbirth. J. Physiol. Biochem. 69, 559–573. https://doi.org/10.1007/s13105-
575 012-0227-2
576 van der Meulen, T., Donaldson, C.J., Cáceres, E., Hunter, A.E., Cowing–Zitron, C., Pound,
577 L.D., Adams, M.W., Zembrzycki, A., Grove, K.L., Huising, M.O., 2015. Urocortin3
578 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat Med 21,
579 769–776. https://doi.org/10.1038/nm.3872
580 Vasavada, R.C., Garcia-Ocaña, A., Zawalich, W.S., Sorenson, R.L., Dann, P., Syed, M.,
581 Ogren, L., Talamantes, F., Stewart, A.F., 2000. Targeted expression of placental lactogen in
582 the beta cells of transgenic mice results in beta cell proliferation, islet mass augmentation,
583 and hypoglycemia. J. Biol. Chem. 275, 15399–15406.
584 Voltolini, C., Battersby, S., Novembri, R., Torricelli, M., Severi, F.M., Petraglia, F., Norman,
585 J.E., 2015. Urocortin 2 Role in Placental and Myometrial Inflammatory Mechanisms at
586 Parturition. Endocrinology 156, 670–679. https://doi.org/10.1210/en.2014-1432
587 Weninger, S.C., Dunn, A.J., Muglia, L.J., Dikkes, P., Miczek, K.A., Swiergiel, A.H.,
588 Berridge, C.W., Majzoub, J.A., 1999. Stress-induced behaviors require the corticotropin-
589 releasing hormone (CRH) receptor, but not CRH. PNAS 96, 8283–8288.
590 https://doi.org/10.1073/pnas.96.14.8283

 Accepted Manuscript published as JOE-19-0568.R1. Accepted for publication: 27-Feb-2020

591 Wierzbicka, J.M., Żmijewski, M.A., Antoniewicz, J., Sobjanek, M., Slominski, A.T., 2017.
592 Differentiation of Keratinocytes Modulates Skin HPA Analog. Journal of Cellular Physiology
593 232, 154–166. https://doi.org/10.1002/jcp.25400
594 Xue, Y., Liu, C., Xu, Y., Yuan, Q., Xu, K., Mao, X., Chen, G., Wu, X., Brendel, M.D., Liu,
595 Chao, 2010. Study on pancreatic islet adaptation and gene expression during pregnancy in
596 rats. Endocrine 37, 83–97. https://doi.org/10.1007/s12020-009-9273-0
597 You, X., Liu, J., Xu, C., Liu, W., Zhu, X., Li, Y., Sun, Q., Gu, H., Ni, X., 2014.
598 Corticotropin-releasing hormone (CRH) promotes inflammation in human pregnant
599 myometrium: the evidence of CRH initiating parturition? J. Clin. Endocrinol. Metab. 99,
600 E199-208. https://doi.org/10.1210/jc.2013-3366
601 Zhang, H., Zhang, J., Pope, C.F., Crawford, L.A., Vasavada, R.C., Jagasia, S.M., Gannon,
602 M., 2010. Gestational Diabetes Mellitus Resulting From Impaired β-Cell Compensation in
603 the Absence of FoxM1, a Novel Downstream Effector of Placental Lactogen. Diabetes 59,
604 143–152. https://doi.org/10.2337/db09-0050
605 Zouboulis, C.C., Seltmann, H., Hiroi, N., Chen, W., Young, M., Oeff, M., Scherbaum, W.A.,
606 Orfanos, C.E., McCann, S.M., Bornstein, S.R., 2002. Corticotropin-releasing hormone: an
607 autocrine hormone that promotes lipogenesis in human sebocytes. Proc. Natl. Acad. Sci.
608 U.S.A. 99, 7148–7153. https://doi.org/10.1073/pnas.102180999

609

610 **Figure legends**

611

612 **Figure. 1:** Expression of *Crhr1* (**A**) and *Crhr2* (**B**) mRNAs by isolated female islets in non-
613 pregnancy (white bar) and pregnancy day 16 (PD.16; black bar). Anterior pituitary was used
614 as a positive control (grey bar) and mRNA expression levels were quantified to the relative
615 expression of housekeeping gene, *Gapdh*. *Crhr1* mRNA expression levels decreased

significantly during pregnancy (~60%) whereas levels of *Crhr2* expression were unchanged. Data are presented as mean + S.E.M., n=5, *p<0.05; Students T-test non-pregnant vs PD.16.

Figure. 2: Effect of exogenous CRH **(A)**, CRHR1 specific agonist Stressin 1 **(C)** and CRHR2 specific agonist UCN2 **(E)** on dynamic insulin secretion from isolated, perifused female mouse islets. Islets were exposed to physiological buffer containing 20 mmol/l glucose only or supplemented with agonists between 30-50 mins. All CRHR agonists potentiated glucose-stimulated insulin secretion over that seen from control islets, as demonstrated by the rate of insulin secretion (**A,C,E**) and area under curve data (**B,D,F)**. Data are presented as mean ± S.E.M., n= 3-4 per treatment group, AUC 20 mmol/l glucose + agonist, 30-50 min, *p<0.05, **p<0.01, ***p<0.001; Students T-test control vs agonist treatment.

Figure. 3: Expression of CRH and urocortins mRNAs in mouse placenta on day 18 of pregnancy (PD.18) **(A)** and circulating concentrations of CRH peptides during mouse pregnancy (PD.16) **(B)**. Expression levels were quantified to the relative expression of housekeeping gene *Gapdh*. *Crh*, *Ucn1*, *Ucn2* and *Ucn3* mRNAs were all expressed by mouse placenta. Plasma levels of CRH, UCN1 and UCN3 were similar in pregnant and non-pregnant mice. However, plasma UCN2 was significantly elevated during pregnancy. Data presented as mean + S.E.M., n=6, ***p<0.001; Two-way ANOVA followed by Tukey's multiple comparisons test.

Figure. 4: Effects of chronic administration of CRHR antagonists on glucose homeostasis during pregnancy **(A-D)** and non-pregnancy **(E-H)**. Pregnant mice (PD.16) treated with either α-helical CRF_{9-41} or AS-30 (Antisauvagine-30) displayed a significant impairment in glucose tolerance 15 mins after glucose loading (2g/kg) when comparison to control mice

 Accepted Manuscript published as JOE-19-0568.R1. Accepted for publication: 27-Feb-2020

641 administered saline (solid black line circle icon). No difference in glucose tolerance was seen
642 in mice administered AH (Antalarmin hydrochloride). AUC from 0-30 min for each
643 treatment group is displayed in panel B. No change in overall insulin sensitivity was observed
644 between all treatment groups **(C)**. AUC from 0-60min for each treatment group is displayed
645 in panel D, (n=7-19). In non-pregnant mice chronic administration of α-helical CRF_{9-41} had
646 no significant effects on glucose tolerance **(E)** or insulin sensitivity **(G)**. AUC for glucose
647 tolerance 0-30 min and insulin sensitivity 0-60 min are displayed in panel F and H
648 respectively, (n=5-6). Data are presented as mean ± S.E.M., # (Control vs α-helical CRF_{9-41}) /
649 * (Control vs AS-30): 15 mins $p<0.05$; Two-way repeated measures ANOVA followed by
650 Tukey's multiple comparisons test.
651
652 **Figure. 5:** Effect of chronic administration of a non-selective CRHR antagonist (α-helical
653 CRF $_{9-41}$) on β-cell morphology during pregnancy. Representative images of immunostaining
654 for the measurement of β-cell proliferation in control **(A)** and α-helical CRF $_{9-41}$ **(B)** islets
655 showing insulin staining (red) and BrdU staining (green). Mice administered BrdU from days
656 14 – 18 of pregnancy displayed no significant differences in the percentage of BrdU labelled
657 β-cells between control and α-helical CRF $_{9-41}$ treated mice **(C)**. Average β-cell size **(D)** and
658 average β-cell islet area **(E)** were also unchanged between control and antagonist treatments.
659 Data presented showing quantification (3-4 sections/animal analysed) for individual animals
660 with bar showing mean, n=8-9 animals per treatment group. Scale bar- 50 μm

Figure 1



209x296mm (300 x 300 DPI)

Accepted Manuscript published as JOE-19-0568.R1. Accepted for publication: 27-Feb-2020

Figure 2



209x296mm (300 x 300 DPI)

Figure 3



209x296mm (300 x 300 DPI)

Accepted Manuscript published as JOE-19-0568.R1. Accepted for publication: 27-Feb-2020

Figure 4



209x296mm (300 x 300 DPI)

Figure 5



209x296mm (300 x 300 DPI)